Antiretroviral drug regimens for HIV usually are changed when they fail or when adverse effects emerge. In a randomized trial, an international research team tested a different strategy ...
Novel regimens must match the high efficacy and safety observed with currently approved HIV treatments and do so with administration that is ideally minimally painful and can be performed outside ...
designed to manage HIV infection, suppress viral load, and improve patient survival rates. With the introduction of once-daily regimens, fixed-dose combinations, and long-acting injectable ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback